Conserved CD4+ T cell staphylococcal and streptococcal epitopes enable broad-acting vaccines in mice
- PMID: 41714815
- DOI: 10.1038/s41564-026-02265-y
Conserved CD4+ T cell staphylococcal and streptococcal epitopes enable broad-acting vaccines in mice
Abstract
Vaccines are effective and much-needed tools against bacterial infection, which mitigate multidrug resistance; however, selection of bacterial antigens that elicit protection and contribute to effective vaccines remains challenging. Here we use immunopeptidomics to identify CD4+ T cell vaccine targets in methicillin-resistant Staphylococcus aureus, a clinically significant, antibiotic-resistant bacterium that is susceptible to T cell-mediated control. We identified a highly conserved, immunodominant CD4+ T cell epitope in S. aureus that is derived from the core DNA-binding protein Hu (Hup). This epitope was shared across a range of clinically relevant streptococcal and staphylococcal species, and cross-species-reactive Hup-specific CD4+ T cells were found in both mice and humans. Immunization of mice with the Hup epitope resulted in the development of broadly protective CD4+ T cell immunity capable of limiting disease severity following infection with S. aureus and Streptococcus pneumoniae. These findings suggest that vaccines incorporating antigens derived from core genes conserved across species might confer broad-spectrum protection against multiple clinically relevant, antibiotic-resistant streptococcal and staphylococcal strains.
© 2026. The Author(s), under exclusive licence to Springer Nature Limited.
Conflict of interest statement
Competing interests: A.W.P. is a member of the scientific advisory board of Bioinformatic Solutions Inc. (Canada) and is a shareholder and scientific advisory board member of Evaxion Biotech (Denmark). He is a co-founder of Resseptor Therapeutics (Australia). None of these entities had any influence on this publication. L.M.W. and J.B. are named as inventors on provisional patent applications filed in Australia by the University of Melbourne covering the use of Hup as a vaccine antigen (2025901634, 2025906738, 2025906739). The other authors declare no competing interests.
References
-
- GBD 2021 Antimicrobial Resistance Collaborators Global burden of bacterial antimicrobial resistance 1990–2021: a systematic analysis with forecasts to 2050. Lancet 404, 1199–1226 (2024). - DOI
Grants and funding
LinkOut - more resources
Full Text Sources
Research Materials
